{"prompt": "['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '20', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'LIST OF TABLES', 'Table 1', 'Adequate Organ Function Laboratory Values', '62', 'Table 2', 'Study Interventions', '68', 'Table 3', 'Dose Modification and Toxicity Management Guidelines for Immune-', 'related Adverse Events Associated with Pembrolizumab Monotherapy,', 'Coformulations or IO Combinations', '75', 'Table 4', 'Pembrolizumab Infusion Reaction Dose Modification and Treatment', 'Guidelines', '80', 'Table 5', 'Summary of Imaging and Treatment Requirements After First', 'Radiologic Evidence of Progression', '95', 'Table 6', 'Reporting Time Periods and Time Frames for Adverse Events and', 'Other Reportable Safety Events', '101', 'Table 7', 'Analysis Methods for Key Efficacy Endpoints', '113', 'Table 8', 'Censoring Rules for Primary and Sensitivity Analyses of Progression-', 'free Survival', '114', 'Table 9', 'Censoring Rules for Duration of Response', '115', 'Table 10', 'Analysis Strategy for Safety Parameters', '117', 'Table 11', 'Protocol-Required Safety Laboratory Assessments', '130', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '21', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', 'LIST OF FIGURES', 'Figure 1', 'Original and Updated Study Design: Initial Treatment Phase', '28', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']['PRODUCT: MK-7902 (E7080/lenvatinib) and MK-3475 (pembrolizumab)', '22', 'PROTOCOL/AMENDMENT NO.: 007-06 (E7080-G000-314)', '1', 'PROTOCOL SUMMARY', '1.1', 'Synopsis', 'Protocol Title: A Phase 3, randomized, double-blind trial of pembrolizumab (MK-3475)', 'with or without lenvatinib (E7080/MK-7902) in participants with treatment-na\u00efve, metastatic', 'nonsmall cell lung cancer (NSCLC) whose tumors have a tumor proportion score (TPS)', 'greater than or equal to 1% (LEAP-007)', 'Short Title: Pembrolizumab with or without lenvatinib in TPS 1% NSCLC', 'Acronym: Protocol 007 (LEAP-007)', 'Hypotheses, Objectives, and Endpoints:', 'NOTE: As of Amendment 007-06, lenvatinib and matching placebo have been removed', 'from the study. All participants remaining on study will continue on open-label', 'pembrolizumab monotherapy. No further analyses of efficacy endpoints will be', 'performed. Exploratory objectives may not be pursued.', 'Participants were screened for up to 28 days, then randomized, and continued study', 'treatment until discontinuation (defined in Section 7.1) OR stop/unblinding of study', 'intervention due to the futility analysis criterion for os being met.', 'In adult participants with treatment-na\u00efve, metastatic NSCLC expressing PD-L1 (TPS >1%):', 'Primary Objectives', 'Primary Endpoints', '- Objective: To compare progression-free', '- PFS, defined as the time from', 'survival (PFS) as assessed by blinded', 'randomization to the first documented', 'independent central review (BICR) according', 'progressive disease (PD) or death due to any', 'to Response Evaluation Criteria in Solid', 'cause, whichever occurs first*', 'Tumors, version 1.1 (RECIST 1.1), adjusted', 'to follow a maximum of 10 target lesions and', 'a maximum of 5 target lesions per organ, for', 'the combinations of pembrolizumab +', 'lenvatinib versus pembrolizumab + matching', 'placebo', '- Hypothesis (H1): The combination of', 'pembrolizumab + lenvatinib has superior PFS', 'per RECIST 1.1, as defined in Section', '4.2.1.1.1, based on BICR', 'MK-7902-007-06 FINAL PROTOCOL', '15-SEP-2021', 'C', 'Confidential']\n\n###\n\n", "completion": "END"}